soul trial oral semaglutide trial: 14 mg demonstrated superior reduction in risk of CV events Oral Semaglutide Cuts Cardiovascular Risk

Patients with neurological involvement require more intensive initial treatment with injections on alternate days until no further improvement occurs

FDA Submission Timeline Based on the TRIUMPH-4 success and expected 2026 readouts, analysts predict: Late 2026: Completion of core TRIUMPH trials Q4 2026 or Q1 2027: New Drug Application (NDA) submission to FDA Mid to Late 2027: Potential FDA approval Early 2028: Commercial launch Eli Lilly has not officially confirmed these timelines, but the company has indicated it will submit for regulatory approval once sufficient Phase 3 data is available

PlexusDx patients benefit from working with their prescribing provider to confirm baseline micronutrient status before adding glutathione or other compounds

Its inclusion in QUAD is a clinician-directed compounding decision, not an FDA-approved use for this indication